|Bid||5.58 x 800|
|Ask||5.61 x 1800|
|Day's Range||5.09 - 5.67|
|52 Week Range||3.14 - 9.53|
|Beta (5Y Monthly)||1.03|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
On Wednesday, Immunovant Inc (NASDAQ: IMVT) announced a new anti-FcRn, IMVT-1402, at Roivant Sciences Ltd's (NASDAQ: ROIV) Investor Day. IMVT-1402 is a new anti-FcRn monoclonal antibody that matches batoclimab's IgG lowering without affecting albumin and LDL. HC Wainwright says the addition of IMVT-1402 broadens the anti-FcRn franchise. The analyst maintains a Buy rating with a price target of $16. Roivant is leveraging data and learnings from batoclimab studies to accelerate IMVT-1402's develop
Immunovant's (IMVT) lead pipeline candidate, batoclimab, is being developed for treating myasthenia gravis, thyroid eye disease and other autoimmune diseases.
Immunovant, Inc. (IMVT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.